Document:

EX-10.17

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Exhibit 10.17 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the
registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

AMENDMENT NO. 1 TO LICENSE AGREEMENT 

This Amendment No. 1 to the License Agreement, dated as of September 24, 2019 (this “Amendment”), is entered into
by and between Novartis International Pharmaceutical AG, a corporation organized under the laws of Switzerland (“Novartis”), and Amplyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware
(“Company”). Novartis and Company are each referred to individually as a “Party” and together as the “Parties”. Except as otherwise expressly provided, capitalized terms used in this Amendment that
are not otherwise defined herein shall have the meanings provided in the License Agreement (as defined below). 
 RECITALS 

WHEREAS, the Parties entered into that certain License Agreement on August 26, 2019 (the “License Agreement”); and 

WHEREAS, the Parties desire to amend the License Agreement to delete Exhibit C thereto and replace it with a new Exhibit C. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual agreements and covenants set forth herein, for other good and
valuable consideration and intending to be legally bound, the Parties hereby agree as follows: 
  

	1.	 AMENDMENT 

  

	1.1	 Exhibit C to the License Agreement is hereby deleted and replaced with the Exhibit C set forth in Annex
A to this Amendment. 

  

	2.	 MISCELLANEOUS 

  

	2.1	 Scope of Amendment. Except as expressly set forth in this Amendment, the terms of the License Agreement
shall remain in full force and effect. 

  

	2.2	 Counterparts. This Amendment may be executed in two or more counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures.

  

	2.3	 Governing Law and Jurisdiction. This Amendment will be governed by and construed under the laws of the
State of New York, USA, without giving effect to the conflicts of laws provision thereof. The United Nations Convention on Contracts for the International Sale of Goods (1980) will not apply to the interpretation of this Amendment.

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 [Signature Page Follows] 

  
 2 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Amendment No. 1 to License Agreement - Signature Page 

IN WITNESS WHEREOF, the Parties, intending to be bound, have caused this Amendment to be executed and delivered by their duly authorized
representatives. 
  

			
	NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
		
	By:	 	 /s/ Simone Pfirter

	Name:	 	Simone Pfirter
	Title:	 	Authorized Signatory
		
	By:	 	 /s/ Charlotte Retzler

	Name:	 	Charlotte Retzler
	Title:	 	Authorized Signatory
	
	AMPLYX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Ciara Kennedy

	Name:	 	Ciara Kennedy
	Title:	 	CEO

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 ANNEX A 

EXHIBIT C 

NOVARTIS PATENTS 
 [***] 

 

  
 Exhibit C - 1EX-4.1

 Exhibit 4.1 

Execution Version 

R. R. DONNELLEY & SONS COMPANY 

and 
 WELLS FARGO BANK,
NATIONAL ASSOCIATION, as Trustee 
  
  

TWELFTH SUPPLEMENTAL INDENTURE 

Dated as of February 7, 2022 

to 
 Indenture dated as
of January 3, 2007 
  
  

6.00% Notes due 2024 

 TABLE OF CONTENTS 

 

							
		 	Article I	  			
			
		 	DEFINITIONS	  			
			
	 Section 1.1
	 	Generally	  	 	4	 
			
		 	Article II	  			
			
		 	AMENDMENTS	  			
			
	 Section 2.1
	 	Certain Amendments to the Indenture	  	 	4	 
	 Section 2.2
	 	Certain Waivers to the Indenture	  	 	7	 
	 Section 2.3
	 	Effectiveness.	  	 	7	 
			
		 	Article III	  			
			
		 	MISCELLANEOUS PROVISIONS	  			
			
	 Section 3.1
	 	Ratification of Indenture	  	 	8	 
	 Section 3.2
	 	Trustee Not Responsible for Recitals	  	 	8	 
	 Section 3.3
	 	Table of Contents, Headings, etc.	  	 	8	 
	 Section 3.4
	 	Counterpart Originals	  	 	8	 
	 Section 3.5
	 	Governing Law; Jury Trial Waiver	  	 	9	 

  
 2 

 THIS TWELFTH SUPPLEMENTAL INDENTURE, dated as of February 7, 2022 (the “Twelfth
Supplemental Indenture”), between R. R. Donnelley & Sons Company, a Delaware corporation, as issuer (the “Company”), and Wells Fargo Bank, National Association, a national banking association, as trustee (the
“Trustee”). 
 RECITALS: 

WHEREAS, the Company has executed and delivered to the Trustee an Indenture, dated as of January 3, 2007 (the “Base Indenture”
and, together with the Tenth Supplemental Indenture (defined below), the “Indenture”), providing for the issuance by the Company from time to time of its unsecured senior debentures, notes or other evidences of indebtedness to be issued in
one or more series unlimited as to principal amount (the “Securities”); 
 WHEREAS, the Company has executed and delivered to the
Trustee a Tenth Supplemental Indenture, dated as of March 20, 2014 (the “Tenth Supplemental Indenture”), to the Base Indenture governing the 6.00% Notes due 2024 (the “Notes”); 

WHEREAS, pursuant to the terms of a consent solicitation statement, dated January 20, 2022 (the “Consent Solicitation
Statement”), the Company solicited consents to certain waivers and amendments to the Indenture with respect to the Notes and other Securities as set forth herein; 

WHEREAS, Section 8.02 of the Base Indenture provides that the Company and the Trustee may amend certain provisions of the Indenture or
the Notes with the consent of the registered holders (the “Holders”) of a majority in aggregate principal amount of the Notes then outstanding (excluding any Notes owned by the Company or any of its Affiliates), and such consent has been
received by the Company; 
 WHEREAS, the Company desires the Trustee to join with it in the execution and delivery of this Twelfth
Supplemental Indenture, and in accordance with Sections 8.02, 8.06 and 10.04 of the Base Indenture, the Company has (i) duly adopted and delivered to the Trustee, resolutions of its Board of Directors authorizing the execution and delivery of
this Twelfth Supplemental Indenture, (ii) delivered to the Trustee evidence reasonably satisfactory to the Trustee that Holders of a majority in aggregate principal amount of the Notes outstanding have given and, as of the date hereof, have not
withdrawn their consents to the amendments set forth in this Twelfth Supplemental Indenture, and (iii) delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel stating that the execution of this Twelfth Supplemental
Indenture is permitted by the Indenture and that all conditions precedent to its execution have been complied with, and the Indenture and this Twelfth Supplemental Indenture are valid and binding obligations of the Company and are enforceable in
accordance with their terms; 
 WHEREAS, all things necessary to make this Twelfth Supplemental Indenture a valid agreement of the Company
and the Trustee, in accordance with its terms, and a valid amendment of, and supplement to, the Indenture have been done; 
 NOW, THEREFORE,
in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company covenants and agrees with the Trustee, for the equal and ratable benefit of the Holders, that
the Indenture is supplemented and amended, to the extent expressed herein, as follows: 

  
 3 

 ARTICLE I 

DEFINITIONS 

Section 1.1 Generally. 

(a) Capitalized terms used herein and not otherwise defined herein shall have the respective meanings ascribed thereto in the Base Indenture.

 (b) The rules of interpretation set forth in the Base Indenture shall be applied hereto as if set forth in full herein. 

ARTICLE II 

AMENDMENTS 

Section 2.1 Certain Amendments to the Indenture. Solely with respect to the Notes, the Indenture is hereby amended
as follows: 
 (a) the definition of “Change of Control” as set forth in Section 1.2 of the Tenth Supplemental Indenture is
hereby deleted in its entirety and replaced with the following: 
 “Change of Control” means the occurrence
of any of the following: (1) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or
assets of the Company and its Subsidiaries taken as a whole to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries or to a Permitted Holder; or (2) the
consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than a Permitted Holder,
becomes the beneficial owner, directly or indirectly, of more than 50% of the then outstanding number of shares of the Company’s voting stock. 

(b) the following definitions are hereby inserted alphabetically into Section 1.2 of the Tenth Supplemental Indenture: 

“CAM” means Chatham Asset Management, LLC, a Delaware limited liability company, together with certain of its
Affiliates. 
 “Permitted Holder” means CAM and its respective Subsidiaries and Affiliates and any person or
group whose acquisition of beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act, or any successor provision) constitutes a Change of Control in respect of which a Change of Control
Offer is made in accordance with the requirements of Section 4.1 hereof (or would result in a Change of Control Offer in the absence of the waiver of such requirement by Holders in accordance with Section 4.1 hereof) shall thereafter
constitute a Permitted Holder. 

  
 4 

 (c) Section 4.08 of the Base Indenture is hereby amended in its entirety to read as follows:

 “So long as any Securities are outstanding, the Company will deliver to the Trustee a copy of all of the information
and reports referred to below: 
 (a) for so long as the Company is subject to the reporting requirements of Section 13
or 15(d) of the Exchange Act: 
 (1) within the time periods specified in the Commission’s rules and regulations, all quarterly and
annual reports on Forms 10-Q and 10-K, including a “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and, with
respect to annual information only, a report thereon by the Company’s certified independent accountants; and 
 (2) all current reports
on Form 8-K; 
 (b) for so long as the Company is not subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act: 
 (1) within 120 days after the end of each fiscal year (or 150 days in the
case of the fiscal year of the Company ended on or around December 31, 2022), annual audited financial statements for such fiscal year, including a “Management’s Discussion and Analysis of Financial Condition and Results of
Operations”, with respect to the periods presented prepared in accordance with GAAP and a report thereon by the Company’s certified independent accountants; 

(2) within 60 days after the end of each of the first three fiscal quarters of each fiscal year, unaudited financial statements (including
footnotes) for the interim period as of, and for the period ending on, the end of such quarter, including a “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the Company with respect to the
periods presented prepared in accordance with GAAP; and 
 (3) promptly after the occurrence of any of the following
events, (and, in any case, not required to be sooner than five Business Days after the occurrence of any such event), current reports of the Company containing substantially all of the information that would be required to be filed
in a current report on Form 8-K under the Exchange Act on April 28, 2021 pursuant to Sections 1 and 4, Items 2.01, 2.03, 2.04(a), 5.01, 5.02(a)(1) (with respect to

  
 5 

 
independent directors only), 5.02(b) (with respect to officers and independent directors only), 5.02(c)(1) and (3), 5.02(d)(1), (2), (3) and (4) (in each case, with respect to independent
directors only) 5.03(b) of Form 8-K (but excluding, for the avoidance of doubt, financial statements and exhibits that would be required pursuant to Item 9.01 of Form
8-K, other than financial statements and pro forma financial information (in each case relating to transactions required to be reported pursuant to Item 2.01 of Form
8-K) to the extent available (as determined in good faith by the Company)) if the Company had been a reporting company under the Exchange Act. 

To the extent any such information is not so filed or furnished, as applicable, within the time periods specified in this
Section 4.08 and such information is subsequently filed or furnished, as applicable, the Company shall be deemed to have satisfied its obligations with respect thereto at such time and any Default with respect thereto shall be deemed to have
been cured; provided that such cure shall not otherwise affect the rights of the Holders under Article SIX hereof if Holders of at least 25% in principal amount of the then total outstanding Securities have declared the principal of, premium,
if any, interest and any other monetary obligations on all the then outstanding Securities to be due and payable immediately and such declaration shall not have been rescinded or cancelled prior to such cure. 

(c) In addition to providing such information to the Trustee, the Company shall make available to Holders the information
required to be provided pursuant to clauses (1), (2) and (3) of the preceding paragraph, by posting such information to its website or on IntraLinks or any comparable password protected online data system or website. 

(d) Notwithstanding the foregoing, (a) the Company will not be required to deliver any information, certificates or
reports that would otherwise be required by (i) Section 302, Section 404 and Section 906 of the Sarbanes-Oxley Act of 2002, or related Items 307 or 308 of Regulation S-K, (ii) Item
10(e) of Regulation S-K promulgated by the Commission with respect to any non-generally accepted accounting principles financial measures contained therein or
(iii) Items 201, 402, 403, 405, 406, 407, 701 or 703 of Regulation S-K, (b) such reports will not be required to contain financial information required by Rule
3-09, Rule 3-10, Rule 13-01 or Rule 13-02 of Regulation
S-X or include any exhibits or certifications required by Form 10-K or Form 10-Q (or any successor forms) or related rules under
Regulation S-K and (c) such reports shall be subject to exceptions, exclusions and other differences consistent with the presentation of financial and other information in this offering memorandum and
shall not be required to present compensation or beneficial ownership information. 

  
 6 

 (e) The Company has agreed that, for so long as any Securities remain
outstanding during any period when the Company is not subject to Section 13 or 15(d) of the Exchange Act, or otherwise permitted to furnish the Commission with certain information pursuant to Rule
12g3-2(b) of the Exchange Act, it will furnish to the Holders and to prospective investors, upon their request, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act.

 (f) Notwithstanding this Section 4.08, the Company will be deemed to have delivered such reports and information
referred to above to the Holders and the Trustee for all purposes of this Indenture if the Company has filed such reports with the Commission via the EDGAR filing system (or any successor system) and such reports are publicly available. In addition,
the requirements of this Section 4.08 will be deemed satisfied and the Company will be deemed to have delivered such reports and information referred to above to the Holders for all purposes of this Indenture by the posting of reports and
information that would be required to be provided on the Company’s website. Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt of such shall not constitute
constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants thereunder (as to which the Trustee is entitled to rely exclusively on an
Officers’ Certificate). The Trustee shall not be obligated to monitor or confirm, on a continuing basis or otherwise, the Company’s compliance with the covenants under this Indenture or with respect to any reports or other documents filed
with the Commission or posted on the Company’s website pursuant to this Indenture, or participate in any conference calls.” 
 (d)
all references to Sections of the Indenture amended by this Twelfth Supplemental Indenture shall mean such Section as amended by this Twelfth Supplemental Indenture. 

Section 2.2 Certain Waivers to the Indenture. Solely with respect to the Notes, the merger of Chatham Delta Acquisition Sub, Inc.,
a Delaware corporation, with and into the Company (the “Merger”) pursuant to the agreement and plan of merger, dated as of December 14, 2021, as amended, restated, amended and restated, supplemented, waived or otherwise
modified from time to time (the “Merger Agreement”), will not constitute a Change of Control under Section 1.2 of the Tenth Supplemental Indenture. For the avoidance of doubt, the Company shall have no obligation to make a
Change of Control Offer pursuant to Section 4.1 of the Tenth Supplemental Indenture in connection with the Merger. 
 Section 2.3
Effectiveness. This Twelfth Supplemental Indenture shall become effective upon the execution and delivery hereof by the parties hereto. Notwithstanding the foregoing, the amendments and waivers set forth above in this Article II shall not
become operative until immediately prior to the consummation of the Merger pursuant to the Merger Agreement and will cease to be operative if the Merger is not consummated or the Consent Consideration (as defined in the Consent Solicitation
Statement) with respect to the Notes is not paid in accordance with the terms of the Consent Solicitation Statement. 

  
 7 

 ARTICLE III 

MISCELLANEOUS PROVISIONS 

Section 3.1 Ratification of Indenture. The Indenture, as supplemented by this Twelfth Supplemental Indenture, is in all
respects ratified and confirmed, and this Twelfth Supplemental Indenture shall be deemed part of the Indenture in the manner and to the extent herein and therein provided. 

Section 3.2 Trustee Not Responsible for Recitals. The recitals contained herein and in the Notes shall be taken as the
statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to and shall not be responsible for the validity or sufficiency of this Twelfth Supplemental Indenture or
of the Notes. The Trustee makes no representations as to and shall not be responsible for the Company’s 6.500% notes due 2023, 6.125% senior secured notes due 2026, 8.250% notes due 2027, 8.500% notes due 2029, 6.625% debentures due 2029 and
8.820% debentures due 2031, the solicitation of consents and the consents of the Holders of the Notes. In entering into this Twelfth Supplemental Indenture, the Trustee shall be entitled to the benefit of every provision of the Indenture relating to
the conduct or affecting the liability of or affording protection to the Trustee, whether or not elsewhere herein so provided. The Company hereby confirms to the Trustee that this Twelfth Supplemental Indenture has not resulted in a material
modification of the Notes for Foreign Account Tax Compliance Act (“FATCA”) purposes. The Trustee shall assume that no material modification for FATCA purposes has occurred regarding the Notes, unless the Trustee receives written
notice of such modification from the Company. 
 Section 3.3 Table of Contents, Headings, etc. The table of contents and
headings of the Articles and Sections of this Twelfth Supplemental Indenture have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.

 Section 3.4 Counterpart Originals. The parties may sign any number of copies of this Twelfth Supplemental Indenture.
Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Twelfth Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution
and delivery of this Twelfth Supplemental Indenture as to the parties hereto and may be used in lieu of the original Twelfth Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to
be their original signatures for all purposes. This Twelfth Supplemental Indenture and any certificate, agreement or other document to be signed in connection with this Twelfth Supplemental Indenture and the transactions contemplated hereby shall be
valid, binding, and enforceable against a party when executed and delivered by an authorized individual on behalf of the party by means of (i) an original manual signature; (ii) a faxed, scanned, or photocopied manual signature or
(iii) any other electronic signature permitted by the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act and/or any other relevant electronic signatures law, including
any relevant provisions of the Uniform Commercial Code (collectively, “Signature Law”), in each case to the extent applicable. Each faxed, scanned or photocopied manual signature, or other electronic signature, shall for all
purposes have the same validity, 

  
 8 

 
legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no liability with respect to, any faxed,
scanned or photocopied manual signature, or other electronic signature, of any other party and shall have no duty to investigate, confirm or otherwise verify the validity or authenticity thereof. This Twelfth Supplemental Indenture may be executed
in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute one and the same instrument. For the avoidance of doubt, original manual signatures shall be used for execution or
indorsement of writings when required under the Uniform Commercial Code or other Signature Law due to the character or intended character of the writings. 

Section 3.5 Governing Law; Jury Trial Waiver. THIS TWELFTH SUPPLEMENTAL INDENTURE AND THE NOTES SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING
OUT OF OR RELATING TO THIS TWELFTH SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 [Signature Pages Follow] 

  
 9 

 IN WITNESS WHEREOF, the parties have caused this Twelfth Supplemental Indenture to be duly
executed all as of the date and year first written above. 
  

			
	R. R. DONNELLEY & SONS COMPANY
		
	By:	 	 /s/ Terry D. Peterson

		 	Name: Terry D. Peterson
		 	Title: Executive Vice President and
		 	          Chief Financial Officer

 [Twelfth Supplemental Indenture] 

 
					
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee
	
	By: Computershare Trust Company, N.A. as agent and attorney-in-fact
		
	By:	 	 /s/ Ryan Thomas

		 	Name: Ryan Thomas
		 	Title: Vice President

 [Twelfth Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]